Dupixent Approvals Expand Regeneron's Immunology Reach And Valuation Debate [Yahoo! Finance]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Yahoo! Finance
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Regeneron Pharmaceuticals (NasdaqGS:REGN) and Sanofi received FDA approval for Dupixent to treat allergic fungal rhinosinusitis in adults and children. This is the first FDA approval for a treatment specifically targeting allergic fungal rhinosinusitis. The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending Dupixent for pediatric chronic spontaneous urticaria in the EU. Regeneron, through its partnership with Sanofi, has built Dupixent into a key drug in allergic and inflammatory diseases, and these decisions add two more indications to that story. For investors watching NasdaqGS:REGN, the latest approvals expand Dupixent's potential reach into conditions where treatment options can be limited, especially for younger patients. They also reinforce the company's focus on immunology alongside its e
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- Regeneron Pharmaceuticals (REGN) is now covered by Barclays PLC. They set an "overweight" rating and a $923.00 price target on the stock.MarketBeat
- Regeneron Announces Investor Conference Presentation [Yahoo! Finance]Yahoo! Finance
- Regeneron Announces Investor Conference PresentationGlobeNewswire
- 2 Biotech Giants to Buy in 2026 [Yahoo! Finance]Yahoo! Finance
- Jim Cramer Says “I Should Have Pulled the Trigger on Regeneron” [Yahoo! Finance]Yahoo! Finance
REGN
Earnings
- 1/30/26 - Beat
REGN
Sec Filings
- 3/3/26 - Form 4
- 2/23/26 - Form 4
- 2/19/26 - Form 144
- REGN's page on the SEC website